Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lamp
31 mars 2021 03h40 HE
|
Biofrontera AG
Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the...
Biofrontera submits study report of pharmacokinetics study to FDA
24 févr. 2021 08h30 HE
|
Biofrontera AG
Leverkusen, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces the...
Biofrontera AG: Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021
02 févr. 2021 10h35 HE
|
Biofrontera AG
Leverkusen, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical...
Biofrontera announces preliminary revenue figures for the full year 2020
08 janv. 2021 09h35 HE
|
Biofrontera AG
Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Cologne Higher Regional Court grants approval of capital increase
07 janv. 2021 11h45 HE
|
Biofrontera AG
Leverkusen, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the...
Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz® in Scandinavia
07 déc. 2020 09h10 HE
|
Biofrontera AG
Leverkusen, Germany, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Galenica AB, Malmö,...
Biofrontera AG resolves mandatory conversion of subordinated mandatory convertible bonds
12 nov. 2020 04h27 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has issued a 1.00%...
Biofrontera reports third quarter and first nine months 2020 results
11 nov. 2020 07h00 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today published its...
Biofrontera announces conference call to be held on November 12, 2020 to discuss Q3 2020 financial results
02 nov. 2020 08h00 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Biofrontera AG: Receives reasons from the Federal Court of Justice for overturning ruling of the Cologne Higher Regional Court
14 oct. 2020 04h30 HE
|
Biofrontera AG
Leverkusen, Germany, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, had announced on...